Results 161 to 170 of about 19,006 (184)

Effectiveness of caplacizumab in the first-line treatment for acquired thrombotic thrombocytopenic purpura: single center experience. [PDF]

Ther Adv Hematol
Belakova KM, Pizurova R, Simurda T, Plamenova I, Holly P, Skornova I, Agouba SM, Drotarova M, Brunclikova M, Stryckova A, Jusko R, Stasko J, Sokol J, Jezikova A.   +13 more
europepmc   +1 more source

A 30-minute intravenous infusion of rituximab is safe and cost-effective (SpeedR). [PDF]

Ann Hematol
Wahlin BE, Ljungqvist M, Falk O, Rådman T, Lindé S, Sonnevi K.   +5 more
europepmc   +1 more source

Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura. [PDF]

Front Immunol
Yokota Y, Hara M, Nakajima H.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

Lancet, The, 2023
Nami Okamoto, Ivan Foeldvari, Hermine I Brunner   +2 more
exaly  

Idiopathic inflammatory myopathies

Nature Reviews Disease Primers, 2021
Ingrid E Lundberg, Manabu Fujimoto, Jiri Vencovsky   +2 more
exaly  

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Lancet, The, 2011
Carlo Albera, Ulrich Costabel, Talmadge E King Jr   +2 more
exaly  

Idiopathic pulmonary fibrosis

Lancet, The, 2017
Luca Richeldi, Mark G Jones
exaly  

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

Lancet, The, 2008
Masaaki Mori, Takako Miyamae, Minako Tomiita   +2 more
exaly  

New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis

Lancet, The, 2012
Isis E Fernandez, Oliver Eickelberg
exaly